87 related articles for article (PubMed ID: 9230204)
1. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.
Friedman HS; Johnson SP; Dong Q; Schold SC; Rasheed BK; Bigner SH; Ali-Osman F; Dolan E; Colvin OM; Houghton P; Germain G; Drummond JT; Keir S; Marcelli S; Bigner DD; Modrich P
Cancer Res; 1997 Jul; 57(14):2933-6. PubMed ID: 9230204
[TBL] [Abstract][Full Text] [Related]
2. Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts.
Tagliabue G; Citti L; Massazza G; Damia G; Giavazzi R; D'Incalci M
Anticancer Res; 1992; 12(6B):2123-5. PubMed ID: 1295458
[TBL] [Abstract][Full Text] [Related]
3. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
[TBL] [Abstract][Full Text] [Related]
4. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
5. Response of cultured human cell lines from rhabdomyosarcoma xenografts to treatment with chloroethylnitrosoureas.
Smith DG; Brent TP
Cancer Res; 1989 Feb; 49(4):883-6. PubMed ID: 2521455
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
[TBL] [Abstract][Full Text] [Related]
7. O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.
Schold SC; Brent TP; von Hofe E; Friedman HS; Mitra S; Bigner DD; Swenberg JA; Kleihues P
J Neurosurg; 1989 Apr; 70(4):573-7. PubMed ID: 2926498
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.
Lilley ER; Elion GB; Dewhirst MW; Schold SC; Blum MR; Savina PM; Laskowitz DT; Bigner DD; Friedman HS
Cancer Res; 1991 Aug; 51(15):3906-9. PubMed ID: 1855207
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.
Hare CB; Elion GB; Colvin OM; Ali-Osman F; Griffith OW; Petros WP; Keir S; Marcelli SL; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 1997; 40(5):409-14. PubMed ID: 9272117
[TBL] [Abstract][Full Text] [Related]
10. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786
[TBL] [Abstract][Full Text] [Related]
11. Genomic instability and tolerance to alkylating agents.
Karran P; Hampson R
Cancer Surv; 1996; 28():69-85. PubMed ID: 8977029
[TBL] [Abstract][Full Text] [Related]
12. O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.
Brent TP; Houghton PJ; Houghton JA
Proc Natl Acad Sci U S A; 1985 May; 82(9):2985-9. PubMed ID: 3857628
[TBL] [Abstract][Full Text] [Related]
13. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents.
Kokkinakis DM; Ahmed MM; Delgado R; Fruitwala MM; Mohiuddin M; Albores-Saavedra J
Cancer Res; 1997 Dec; 57(23):5360-8. PubMed ID: 9393761
[TBL] [Abstract][Full Text] [Related]
14. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
Pawlik CA; Israel M; Sweatman TW; Lothstein L
Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
[TBL] [Abstract][Full Text] [Related]
15. Differential repair of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea-induced DNA damage in two human colon tumor cell lines.
Erickson LC; Osieka R; Kohn KW
Cancer Res; 1978 Mar; 38(3):802-8. PubMed ID: 626984
[TBL] [Abstract][Full Text] [Related]
16. Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Friedman HS; Dolan ME; Pegg AE; Marcelli S; Keir S; Catino JJ; Bigner DD; Schold SC
Cancer Res; 1995 Jul; 55(13):2853-7. PubMed ID: 7796412
[TBL] [Abstract][Full Text] [Related]
17. Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents.
Levati L; Marra G; Lettieri T; D'Atri S; Vernole P; Tentori L; Lacal PM; Pagani E; Bonmassar E; Jiricny J; Graziani G
Genes Chromosomes Cancer; 1998 Oct; 23(2):159-66. PubMed ID: 9739019
[TBL] [Abstract][Full Text] [Related]
18. [Expression of extraneuronal monoamine transporter gene and DNA repair gene vis-à-vis with antitumor efficacy of SarCNU in human tumor xenografts].
Chen Z; Panasci LC; Carter CA
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):122-4. PubMed ID: 11783015
[TBL] [Abstract][Full Text] [Related]
19. Duke researchers link brain tumor drug resistance to mismatch repair deficiency.
Compr Ther; 1997 Sep; 23(9):622-3. PubMed ID: 9285166
[No Abstract] [Full Text] [Related]
20. Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6.
Umar A; Koi M; Risinger JI; Glaab WE; Tindall KR; Kolodner RD; Boland CR; Barrett JC; Kunkel TA
Cancer Res; 1997 Sep; 57(18):3949-55. PubMed ID: 9307278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
